Meningococcal conjugate vaccines

Bibliography

• WHO: Meningococcal meningitis. Wkly Epidemiol. Rec. (2003) 78:294–296.
   PubMedGoogle Scholar
• HARRISON L, PASS M, MENDELSOHN A et al.: Invasive menningococcal disease in adolescents and young adults. JAMA (2001) 286(6):694–699.
   PubMed Web of Science ®Google Scholar
• •Description of disease in university students.
   Google Scholar
• CDC: Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR (2000) 19(RR-7):1–10.
   Google Scholar
• NEAL KR, NGUYEN-VAN-TAM J, MONK P et al.: Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation. Epidemiol Infect. (1999) 122(3):351–357.
   PubMed Web of Science ®Google Scholar
• BRUNDAGE JF, RYAN MA, FEIGHNER BH et al.: Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin. Infect. Dis. (2002) 35(11):1376–1381.
   PubMed Web of Science ®Google Scholar
• SPIEGEL A, QUENEL P, SPERBER G et al.: [Evaluation of systematic anti-meningococcal vaccination strategy in French military recruits]. Sante (1996) 6(6):383–388.
   PubMedGoogle Scholar
• GROSECLOSE SL, BRATHWAITE WS, FIALL PA et al.: Summary of notifiable diseases-United States 2002. MMWR Morb. Mortal. Wkly Rep. (2004) 51(53):1–84.
   PubMedGoogle Scholar
• SQUIRES SG, DEEKS SL,TSANG RS: Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can. Commun. Dis. Rep. (2004) 30(3):17–28.
   PubMedGoogle Scholar
• ROSENSTEIN N, PERKINS B, STEPHENS D et al.: The changing epidemiology of meningococcal disease in the United States, 1992–1996.1 Infect. Dis. (1999) 180:1894-1901. A discussion of changing serogroups over time.
   Google Scholar
• APICELLA M: Neisseria meningitidis. In: Principles of Infectious Diseases. Mandell G, Bennett J, Dolin R (Eds), Churchill Livingstone, New York, NY, USA (1995):1896–1909.
   Google Scholar
• JODAR L, FEAVERS IM, SALISBURY D et al.: Development of vaccines against meningococcal disease. Lancet (2002) 359(9316):1499–1508.
   PubMed Web of Science ®Google Scholar
• GRANOFF D, FEAVERS IM, BORROW R: Meningococcal vaccines. In: Vaccines, 4th Edition. Plotkin SA, Orensein WA (Eds), WB Sanders, Philadelphia, PA, USA (2004).
   Google Scholar
• ROSENSTEIN N, PERKINS B, STEPHENS D et al.: Meningococal disease. N Engl. J. Med. (2001) 344(101378–1388. A comprehensive and authoritative review.
   Google Scholar
• SCHUCHAT A, ROBINSON K, WENGER J et al.: Bacterial meningitis in the United States in (1995) N Engl. J. Med. (1997) 337:970–976.
   Google Scholar
• CLAUS H, MAIDEN MC, MAAG R et al.: Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology (2002) 148(Pt 6):1813–1819.
   PubMedGoogle Scholar
• VOGEL U, CLAUS H, VON MULLER L et al.: Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). J. Clin. Microbiol (2004) 42(7):2898–2901.
   Google Scholar
• HOANG LM, THOMAS E, TYLER S et al.: Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin. Infect. Dis. (2005) 40(5):e38–e42.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ B, MOORE PS, BROOME CV: Global epidemiology of meningococcal disease. Clin. Microbiol. Rev. (1989) 2(Suppl.):S118–S124.
   Google Scholar
• GREENWOOD BM, BLAKEBROUGH IS, BRADLEY AK et al.: Meningococcal disease and season in sub-Saharan Africa. Lancet (1984) 1(8390):1339–1342.
   PubMed Web of Science ®Google Scholar
• GREENWOOD B: Manson Lecture. Meningococcal meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg-. (1999) 93(4):341–353.
   PubMed Web of Science ®Google Scholar
• WYLE FA, ARTENSTEIN MS, BRANDT BL et al.: Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. (1972) 126(5):514–521.
   PubMed Web of Science ®Google Scholar
• FINNE J, LEINONEN M, MAKELA PH: Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 2(8340:355–357.
   PubMedGoogle Scholar
• FINNE J, BITTER-SUERMANN D, GORIDIS C et al.: An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol (1987) 138(12):4402–4407.
   PubMed Web of Science ®Google Scholar
• SACCHI CT, WHITNEY AM, POPOVIC T et al.: Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998.1 Infect. Dis. (2000) 182(4):1169–1176.
   Google Scholar
• ZANG WILL KM, SCHUCHAT A, RIEDO FX et al.: School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. JANIA (1997) 277(5):389–395.
   Google Scholar
• JACKSON LA, SCHUCHAT A. REEVES MW et al.: Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA (1995) 273(5):383–389.
   Google Scholar
• FINN R, GROVES C, COE M et al.: Cluster of serogroup C meningococcal disease associated with attendance at a party. South Med. J. (2001) 94(12):1192–1194.
   PubMed Web of Science ®Google Scholar
• WHALEN CM, HOCKIN JC, RYAN A et al.: The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA (1995) 273(5):390–394.
   PubMed Web of Science ®Google Scholar
• KOPPES GM, ELLENBOGEN C,GEBHART RJ: Group Y meningococcal disease in United States Air Force recruits. Am. J. Med. (1977) 62(5):661–666.
   PubMed Web of Science ®Google Scholar
• SMILACK JD: Group-Y meningococcal disease. Twelve cases at an army training center. Ann. Intern. Med. (1974) 81(0:740–745.
   Google Scholar
• GALAID El, CHERUBIN CE, MARR JS et al.: Meningococcal disease in New York City, 1973 to 1978 Recognition of groups Y and W-135 as frequent pathogens. JAMA (1980) 244(19):2167–2171.
   PubMed Web of Science ®Google Scholar
• JACKSON LA,WENGER JD: Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC SurveilL Summ. (1993) 42(2):21–30.
   PubMedGoogle Scholar
• MAYER LW, REEVES MW, AL-FIAMDAN Net al.: Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J. Infect. Dis. (2002) 185(11):1596–1605.
   Google Scholar
• POPOVIC T, SACCHI CT, REEVES MW et al.: Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg. Infect. Dis. (2000) 6(4):428–429.
   PubMed Web of Science ®Google Scholar
• TAHA MK, ACHTMAN M, ALONSO JM et al.: Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet (2000) 356(9248):2159.
   PubMed Web of Science ®Google Scholar
• TAHA MK, GIORGINI D, DUCOS-GALAND M et al.: Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in (2000)1 Clin. MicrobioL (2004) 42(9):4158–4163.
   Web of Science ®Google Scholar
• TAHA MK, PARENT DU CHATELET I, SCHLUMBERGER M et al.: Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J. Clin. MicrobioL (2002) 40(3):1083–1084.
   Google Scholar
• DECOSAS J, KOAMA JB: Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect. Dis. (2002) 2(12):763–765.
   PubMed Web of Science ®Google Scholar
• BAND JD, CHAMBERLAND ME, PLATT T et al.: Trends in meningococcal disease in the United States, 1975-1980. J. Infect. Dis. (1983) 148(4):754–758.
   PubMed Web of Science ®Google Scholar
• ARTENSTEIN M, GOLD R, ZIMMERLY J et al.: Prevention of meningococcal disease by Group C polysaccharide vaccine. N Engl. J. Med. (1970) 282:417–420.
   PubMed Web of Science ®Google Scholar
• •Classic study of meningococcal C vaccine efficacy in adults.
   Google Scholar
• GOLD R, ARTENSTEIN MS: Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–70. Bull. World Health Organ. (1971) 45(3):279–282.
   Google Scholar
• ROSENSTEIN N, LEVINE 0, TAYLOR J et al.: Efficacy of meningococcal vaccine and barriers to vaccination. JAMA (1998) 279(6):435–439.
   Google Scholar
• HARRISON LH, DWYER DM, MAPLES CT et al.: Risk of meningococcal infection in college students. JAMA (1999) 281(20):1906–1910.
   PubMed Web of Science ®Google Scholar
• •Describes risk factors among university students for contracting meningococcal disease.
   Google Scholar
• PELTOLA H, KAYHTY H, KURONEN T et al.: Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. J. Pediatr. (1978) 92(5):818–822.
   Google Scholar
• GOLD R, LEPOW M, GOLDSCHNEIDER I et al.: Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. (1979) 140:670–677.
   Google Scholar
• GRIFFISS JM, BRANDT BL, BROUD DD: Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect. Immun. (1982) 37(1):205–208.
   PubMed Web of Science ®Google Scholar
• GRIFFISS JM, BRANDT BL, ALTIERI PL et al.: Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect. Immun. (1981) 34(3):725–732.
   PubMed Web of Science ®Google Scholar
• ARMAND J, ARMINJON F, MYNARD MC et al.: Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. J. Biol. Stand. (1982) 10(4):335–339.
   PubMedGoogle Scholar
• AMBROSCH F, WIEDERMANN G, CROOY P et al.: Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull. World Health Organ. (1983) 61(2):317–323.
   PubMed Web of Science ®Google Scholar
• VODOPIJA I, BAKLAIC Z, HAUSER P et al.: Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing 0-acetyl-negative or 0-acetyl-positive group C polysaccharide. Infect. Immun. (1983) 42(2):599–604.
   PubMed Web of Science ®Google Scholar
• CADOZ M, ARMAND J, ARMINJON F et al.: Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: immunogenicity and safety. Vaccine (1985) 3(3):340–342.
   PubMed Web of Science ®Google Scholar
• LEPOW ML, BEELER J, RANDOLPH Met al.: Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. Infect. Dis. (1986) 154(6):1033–1036.
   Google Scholar
• PELTOLA H, MAKELA H, KAYHTY H et al.: Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl. J. Med. (1977) 297(13):686–691.
   PubMed Web of Science ®Google Scholar
• •Classic study of meningococcal A vaccine efficacy in children.
   Google Scholar
• WAHDAN MH, SALLAM SA, HASSAN MN et al.: A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull. World Health Organ. (1977) 55(6):645–651.
   PubMed Web of Science ®Google Scholar
• WAHDAN MH, RIZK F, EL-AKKAD AIVI et al.: A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. World Health Organ. (1973) 48(6):667–673.
   PubMed Web of Science ®Google Scholar
• LEPOW M, PERKINS B, HUGHES P et al.: Meningococcal vaccines. In: Vaccines, 3rd ed. Plotkin S (Ed.), W13 Saunders Co, Philadelphia, PA, USA (2003):chapter 34.
   Google Scholar
• ARTENSTEIN MS: Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody. Bull. World Health Organ. (1971) 45(3):291–293.
   Google Scholar
• LEPOW ML, GOLDSCHNEIDER I, GOLD R et al.: Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60(5):673–680.
   PubMed Web of Science ®Google Scholar
• KAYHTY H, KARANKO V PELTOLA H et al.: Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J. Infect. Dis. (1980) 142(61:861–868.
   Google Scholar
• ZANG WILL K, STOUT R, CARLONE Get al.: Duration of antibody response after meningococal polysaccharide vaccination in US Air Force personnel. J. Infect. Dis. (1994) 169:847–852.
   Google Scholar
• REINGOLD A, BROOME C, HIGHTOWER A et al.: Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet (1985) 2:114–118.
   PubMed Web of Science ®Google Scholar
• CEESAY S, ALLEN S, MENON A et al.:Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect on booster immunization. J. Infect. Dis. (1993) 167:1212–1216.
   PubMed Web of Science ®Google Scholar
• BLAKEBROUGH IS, GREENWOOD BM, WHITTLE HC et al.: Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys. Ann. Trop. Med. Parasitol (1983) 77(2):175–178.
   PubMed Web of Science ®Google Scholar
• BROOME CV: The carrier state: Neisseria meningitidis. J. Antimicrob. Chemother. (1986) 18(Suppl. A):25–34.
   Google Scholar
• GREENWOOD BM, HASSAN-KING M, WHITTLE HC: Prevention of secondary cases of meningococcal disease in household contacts by vaccination. Br. Med. J. (1978) 1(6123):1317–1319.
   PubMed Web of Science ®Google Scholar
• MACDONALD NE, HALPERIN SA, LAW BJ et al.: Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?JAMA (2000) 283(14):1826–1827.
   PubMed Web of Science ®Google Scholar
• MACDONALD NE, HALPERIN SA, LAW BJ et al.: Induction of immunologic memory by conjugated versus plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA (1998) 280(19):1685–1689.
   PubMed Web of Science ®Google Scholar
• •Establishes immunological differences between meningococcal polysaccharide and conjugate vaccines.
   Google Scholar
• GRANOFF D, GUPTA R, BELSHE R et al.: Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis. (1998) 178:870–874.
   PubMed Web of Science ®Google Scholar
• DANZIG L: Meningococcal vaccines. Pediatr. Infect. Dis. J. (2004) 23(12 Suppl.):5285–5292.
   Google Scholar
• SCHEIFELE DW, BJORNSON G, BORASTON S: Local adverse effects of meningococcal vaccine. Can. Med. Assoc. J. (1994) 150(1):14–15.
   Web of Science ®Google Scholar
• GOLD R, LEPOW ML, GOLDSCHNEIDER I et al.: Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. j Clin. Invest. (1975) 56(6):1536–1547.
   PubMed Web of Science ®Google Scholar
• YERGEAU A, ALAIN L, PLESS R et al.: Adverse events temporally associated with meningococcal vaccines. Can. Med. Assoc. J. (1996) 154(4):503–507.
   Web of Science ®Google Scholar
• ROBERTS JS, BRYETT KA: Incidence of reactions to meningococcal A&C vaccine among U.K. schoolchildren. Public Health (1988) 102(5):471–476.
   Google Scholar
• LESINSKI GB, WESTERINK MA: Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord. (2001) 1(3):325–334.
   PubMedGoogle Scholar
• LESINSKI GB, WESTERINK MA: Novel vaccine strategies to T-independent antigens. J. Microbiol Methods (2001) 47(2):135–149.
   PubMed Web of Science ®Google Scholar
• STEIN KE: Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. (1992) 165\(Suppl. 1):549–552.
   Google Scholar
• MAIDEN MC, STUART JM: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet (2002) 359(9320):1829–1831.
   PubMed Web of Science ®Google Scholar
• RAMSAY M, ANDREWS N, TROTTER C et al.: Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J. (2003) 326:365–366.
   PubMed Web of Science ®Google Scholar
• •Epidemiological study to establish that meningococcal C conjugate vaccine produces herd immunity.
   Google Scholar
• TWUMASI PA JR, KUMAH S, LEACH A et al.: A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. (1995) 171(3):632–638.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN J, SHIU S, WONG Vet al.: Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in small children-a randomized controlled trial. /AMA (1996) 275(19):1499–1503.
   Google Scholar
• LEACH A, TWAMASI P, KUMAN S et ell.: Induction of immunologic memory in gambian children by vaccination in infancy with group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. (1997) 175:200–204.
   Google Scholar
• MACLENNAN J, OBARO S, DEEKS J et al.: Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine (1999) 17(23-24):3086–3093.
   PubMed Web of Science ®Google Scholar
• RICHMOND P, BORROW R, MILLER E et al.: Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. (1999) 179:1569–1572.
   PubMed Web of Science ®Google Scholar
• BORROW R, GOLDBLATT D, ANDREWS N et al.: Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis. (2002) 186:1353–1357.
   PubMed Web of Science ®Google Scholar
• MC VERNON J, MACLENNAN J, BUTTERY J et al.: Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr. Infect. Dis. j (2002) 21:747–753.
   PubMed Web of Science ®Google Scholar
• MACLENNAN J, OBARO S, DEEKS J et al.: Immunologic memory of 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. (2001) 183:97–104.
   PubMed Web of Science ®Google Scholar
• TROTTER CL, ANDREWS NJ, KACZMARSKI EB et al.: Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 364(9431):365–367.
   PubMed Web of Science ®Google Scholar
• MILLER E, SALISBURY D, RAMSAY k Planning, registration, and implementation of an immunisation campaign against meningcorral serogroup C disease in the UK: a success story. Vaccine (2002) 20(Suppl.):558–567.
   Google Scholar
• •An onverview of the meningococcal C conjugate vaccine success in the UK.
   Google Scholar
• BALMER P, BORROW R, MILLER E: Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol (2002) 51(9):717–722.
   PubMed Web of Science ®Google Scholar
• KEYSERLING H, PAPA T, BYBEL M: A comparative trial of the safety and immunogenicity of an experimental tetravalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine versus a licensed meningococcal (A, C, Y, and W-135) polysaccharide vaccine in healthy adolescents. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA September (2003).
   Google Scholar
• KEYSERLING H, KORANYI K, PAPA T, BYBEL M, RYALL R: Persistence of immune response and duration of memory from a meningococcal (groups A,C,Y, W135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4), 2005 Pediatric Academic Societies. Pediatric Res. (2005):Abstract 75013.
   Google Scholar
• KEYSERLING HL, ROTHSTEIN E, BLATTER M, RYALL RL, BYBEL M, PAPA T: Augmentation of the immune response to a quadrivalent meningococcal 9A,C,Y,W-135) diphtheria conjutate vaccine (MCV-4) by co-administration with tetanus-diphtheria vaccine (Td) in healthy adolescents. 42nd Annual Meeting of Infectious Diseases Society ofAmerica. Boston, MA, USA (2004):Abstract 1044.
   Google Scholar
• PICHICHERO M, CASEY J, BLATTER M et al.: Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr. Infect. Dis. J. (2005) 24(1):57–62.
   PubMed Web of Science ®Google Scholar
• GRANOFF D, MORGAN A, WELSCH A: Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr. Infect. Dis. J. (2005) 24(2):132–136.
   PubMed Web of Science ®Google Scholar
• SHEPARD CW, ORTEGA-SANCHEZ IR, SCOTT RD 2ND et al.: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics (2005) 115(5):1220–1232.
   Google Scholar
• TROTTER CL, EDMUNDS WJ: Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Br. Med. J. (2002) 324(7341):809.
   PubMed Web of Science ®Google Scholar
• BILUKHA 00, ROSENSTEIN N; NATIONAL CENTER FOR INFECTIOUS DISEASES, CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2005) 54(RR-7):1–21.
   Google Scholar
• DE ANDRADE CARVALHO A, GIAMPAGLIA CM, KIMURA H et al.: Maternal and infant antibody response to meningococcal vaccination in pregnancy. Lancet (1977) 2(8042):809–811.
   Google Scholar
• LETSON GW, LITTLE JR, OTTMAN J et al.: Meningococcal vaccine in pregnancy: an assessment of infant risk. Pediatr. Infect. Dis. J. (1998) 17(3):261–263.
   PubMed Web of Science ®Google Scholar
• MCCORMICK JB, GUSMAO HH, NAKAMURA S et al.: Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. Clin. Invest. (1980) 65(5):1141–1144.
   Google Scholar
• ATKINSON WL, PICKERING LK, SCHWARTZ B et al.: General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MIVIWR Recomm. Rep. (2002) 51(RR-2):1–35.
   Google Scholar
• LINGAPPA J, ROSENSTEIN N, ZELL E et al.: Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine (2001) 19:4566–4575.
   PubMedGoogle Scholar
• DE MORAES JC, PERKINS BA, CAMARGO MC et al.: Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 340(8827):1074–1078.
   PubMed Web of Science ®Google Scholar
• BJUNE G, GRONNESBY JK, HOIBY EA et al.: Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. (1991) 14(2):125–130; discussion 130–132.
   Google Scholar
• GRIFFISS JM, YAMASAKI R, ESTABROOK M et al.: Meningococcal molecular mimicry and the search for an ideal vaccine. Trans. R. Soc. Trop. Med. Hyg-. (1991) 85\(Suppl. 1):32–36.
   Google Scholar
• TONDELLA ML, POPOVIC T, ROSENSTEIN NE et al.: Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol (2000) 38(9):3323–3328.
   Google Scholar
• THOMPSON EA, FEAVERS IM, MAIDEN MC: Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology (2003) 149(Pt 7):1849–1858.
   PubMed Web of Science ®Google Scholar
• BOSLEGO J, GARCIA J, CRUZ C et al: Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 13(9):821–829.
   Google Scholar
• FISCHER M, CARLONE GM, HOLST J et al: Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease. Vaccine (1999) 17(19):2377–2383.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT K, MORRIS R, RUMKE H et al: Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 17(20-21):2612–2619.
   PubMed Web of Science ®Google Scholar
• BJUNE G, HOIBY EA, GRONNESBY JK et al: Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 338(8775):1093–1096.
   PubMed Web of Science ®Google Scholar
• SIERRA GV, CAMPA HC, VARCACEL NM et al: Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. (1991) 14(2):195–207; discussion 208–210.
   Google Scholar
• NORONHA CP, STRUCHINER CJ, HALLORAN ME: Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol (1995) 24(5):1050–1057.
   PubMed Web of Science ®Google Scholar
• BJUNE G: 'Herd immunity' and the meningococcal vaccine trial in Norway. Lancet (1992) 340(8814):315.
   PubMed Web of Science ®Google Scholar
• http://www.who.indemc-documents/ meningitis/whoemcbac983c.html World Health Organization. Control of Epidemic Meningococcal Disease. WHO Practical Guidelines. WHO/EMC/BAC/98.3ed Geneva Switzerland, World Health Organization (1998). Accessed 12 April 2005.
   Google Scholar
• http://www.euibis.org/meningo/ meninco_reports.htm European Union Invasive Bacterial Infection Surveillance Network. Invasive Neisseria meningitidis in Europe (2002) (2003). Accessed 12 April 2005.
   Google Scholar